James Leyden, MD
Enriched profileDermatologist · Hospital of the University of Pennsylvania
James Leyden is Dermatologist at Hospital of the University of Pennsylvania. OpenAlex indexes 20 publications with 623 citations (h-index 10); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.
Data verified 4 Nov 2026
Overview
Updated 5 Nov 2026
James Leyden, MD, is Dermatologist at Hospital of the University of Pennsylvania. The public record shows 20 publications with 623 citations (h-index 10), centered on Acne / Hidradenitis, Acne Vulgaris, Erythema. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 4 companies, 1 NIH-funded awards (2000–2002).
- Top research focus: Acne / Hidradenitis
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 4 companies
Generated from the cited public record · current as of 5 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mauiderm.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 5 Nov 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
Sponsor: Novan, Inc.
- Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
Sponsor: Cipher Pharmaceuticals Inc.
Industry payments
Updated 5 Nov 2026
4 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
- Incyte CorporationProgram year20241 payment
- UCB, Inc.Program year20231 payment
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Corticosteroid100%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 5 Nov 2026
1 NIH research award on record, funded 2000–2002 per NIH RePORTER. The latest:
- ACCUTANE NF AND ORAL CONTRACEPTIVE TABLETS IN PREMENOPAUSAL WOMEN W NODULAR ACNE
University of Pennsylvania
FY2002$124,146M01RR000040 - ACCUTANE NF AND ORAL CONTRACEPTIVE TABLETS IN PREMENOPAUSAL WOMEN W NODULAR ACNE
University of Pennsylvania
FY2001$124,146M01RR000040 - ACCUTANE NF AND ORAL CONTRACEPTIVE TABLETS IN PREMENOPAUSAL WOMEN W NODULAR ACNE
University of Pennsylvania
FY2001M01RR000040
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Online presence
Updated 5 Nov 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/james-leyden-md
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
acneandrosacea.org/our-leadership
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →acneandrosacea.org ↗ - Other
solvhealth.com/provider/james-leyden-GN8wzy
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →solvhealth.com ↗ - X / Twitter
Named as Penn Professor Emeritus in a post by Joel Gelfand
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 5 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →acneandrosacea.org ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →accureacne.com ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →c-span.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Mohamed Gad, MD, MPH
Hospital of the University of Pennsylvania
Trinity Bivalacqua, MD
Hospital of the University of Pennsylvania
Selina Luger, MD
Hospital of the University of Pennsylvania
Ian Frank, MD
Hospital of the University of Pennsylvania
Robert Modlin, MD
University of California, Los Angeles
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Joel Gelfand, MD
University of Pennsylvania